Log in Open CFD Account
[Premium Users]
Client Referral Program Affiliate White Label
Log in Open CFD Account
Login Now Open Account
Login Now Open Account

Stop the jab – Johnson & Johnson vaccine rollout paused

14 April 2021 By Klavs Valters

Share

805,734,252 – that’s how many doses of the COVID-19 vaccine have been given globally so far as of the 12th April (from 185 locations), according to Our World in Data. Israel, Bahrain and Chile are leading the way with 54.7%, 24.7% and 24.6% of the population fully vaccinated.

With more and more people getting the jab across the world, the chance of side effects becomes more likely. We have already seen the AstraZeneca vaccine being suspended for use for in few countries. Today, it was announced that the US agencies are calling to pause the Johnson & Johnson vaccine rollout after reports of extremely rare blood clot cases.

Following the FDA and CDC advice, all federal sites in the US have stopped using the vaccine until further investigation.

European Union and South Africa have also confirmed that they will temporally stop the rollout of the Johnson & Johnson jab.

The share price of Johnson & Johnson was down by around 1.34% following the latest news on their vaccine, trading at $159.48 per share the close. The stock is up by 1.57% year-to-date.

Johnson & Johnson – YTD Chart

Source: TradingView

You can trade Johnson & Johnson (JNJ) and many other stocks from the ASX, NYSE, and the NASDAQ with Encrypt Investment as a Share CFD. Click here for more information. Trading Derivatives carries a high level of risk.

Disclaimer: Articles are from Encrypt Investment analysts and contributors and are based on their independent analysis or personal experiences. Views, opinions or trading styles expressed are their own, and should not be taken as either representative of or shared by Encrypt Investment. Advice, if any, is of a ‘general’ nature and not based on your personal objectives, financial situation or needs. Consider how appropriate the advice, if any, is to your objectives, financial situation and needs, before acting on the advice. If the advice relates to acquiring a particular financial product, you should obtain and consider the Product Disclosure Statement (PDS) and Financial Services Guide (FSG) for that product before making any decisions.